A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache
Status:
Completed
Trial end date:
2021-01-21
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess the long-term safety and tolerability of
galcanezumab administered up to once monthly in participants with episodic or chronic cluster
headache who have completed study I5Q-MC-CGAL (NCT02397473) or study I5Q-MC-CGAM
(NCT02438826).